DOCSLIB.ORG

Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 59, No. 22, 2012 © 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.086 STATE-OF-THE-ART PAPER Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection Rakesh C. Kukreja, PHD, Fadi N. Salloum, PHD, Anindita Das, PHD Richmond, Virginia Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may repre- sent a promising therapeutic approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative therapeutic agents for enhancing the chemosensitivity of doxorubicin while providing concurrent cardiac benefit. (J Am Coll Cardiol 2012;59:1921–7) © 2012 by the American College of Cardiology Foundation Cyclic guanosine monophosphate (cGMP) is a critical of cyclic adenosine monophosphate (cAMP) and/or cGMP intracellular second messenger regulating fundamental to produce the corresponding 5’ nucleotide. Currently, 21 physiological processes in the myocardium, from acute PDE genes have been cloned and are classified into 11 contraction/relaxation to chronic gene expression, cell families according to their sequence of homology, biochem- growth, and apoptosis. Several studies have shown that ical, and pharmacological properties (6). The PDEs vary in cGMP inhibits hypertrophy, reduces ischemia-reperfusion their substrate specificity for cAMP and cGMP: PDE-5, (I/R) injury, and regulates contractile function and cardiac PDE-6, and PDE-9 are specific for cGMP; PDE-4, remodeling (1–3). cGMP is generated from the cytosolic PDE-7, and PDE-8 are specific for cAMP; and PDE-1, purine nucleotide guanosine triphosphate by guanylyl cy- PDE-2, PDE-3, PDE-10, and PDE-11 have mixed spec- 2ϩ 2ϩ lases (GCs) using Mg or Mn as cofactors. Two ificity for cAMP/cGMP (7). PDE-5 selectively hydrolyzes isoforms of GCs exist in vertebrate cells and tissues: a nitric cGMP, and its inhibition increases cGMP bioavailability. oxide (NO)-sensitive cytosolic or soluble guanylyl cyclase The abundance of PDE-5 in smooth muscles and its role in (sGC) and natriuretic peptide (NP)-activated plasma mem- regulating their contractile tone has made PDE-5 an brane bound, particulate guanylyl cyclase (pGC). Once important drug target for the treatment of erectile dysfunc- produced, the effects of cGMP occur through 3 main groups tion (6), leading to the development of potent PDE-5 of cellular target molecules: cyclic guanosine monophos- inhibitors, such as sildenafil (Viagra and Revatio, Pfizer, phate–dependent protein kinases (PKGs), cGMP-gated New York, New York), vardenafil (Levitra, Bayer Schering cation channels, and phosphodiesterases (PDEs). cGMP Pharma AG, Leverkusen, Germany), and tadalafil (Cialis positively regulates PKG but inhibits/activates PDEs, and Adcirca, Eli Lilly Canada Inc., Toronto, Ontario, which are predominant in the cardiovascular system (4,5). Canada). Revatio and Adcirca have also been approved for This paper reviews many of the latest findings on cGMP related to the cardioprotection. the treatment of pulmonary hypertension. Earlier studies found that PDE-5 is not present in normal cardiomyocytes Regulation of cGMP by PDEs (8,9), although later investigations revealed its expression in canine (10), mouse cardiomyocytes (1,11,12), and human The cGMP pool in the cell is tightly controlled by PDEs, heart (13,14). PDE-5 expression is increased in hypertro- which specifically cleave the 3=,5=-cyclic phosphate moiety phic human right ventricle, as well as failing left ventricular tissue (13–15). A gene silencing model also confirmed From the Pauley Heart Center, Division of Cardiology, Department of Internal PDE-5 protein expression (16), whereas a recent report still Medicine, Virginia Commonwealth University, Richmond, Virginia. This study was questioned its presence in adult mouse cardiac myocytes supported by grants from the National Institutes of Health (HL51045, HL79424, (17). Because cGMP-hydrolytic activity is also attributable and HL93685) to Dr. Kukreja and a National Scientist Development Grant from the American Heart Association (10SDG3770011) to Dr. Salloum. The authors have to PDE-1 and PDE-3, Vandeput et al. (14) suggested that reported that they have no relationships relevant to the contents of this paper to the effects of sildenafil on cGMP hydrolysis were due to disclose. Manuscript received July 6, 2011; revised manuscript received September 15, 2011, inhibition of both PDE-5 and PDE-1 in the left ventricles accepted September 20, 2011. of normal and failing mouse hearts. 1922 Kukreja et al. JACC Vol. 59, No. 22, 2012 cGMP Signaling in Cardioprotection May 29, 2012:1921–7 Abbreviations cGMP in Pre- and concentrations. ANP is primarily stored in atrial granules and and Acronyms Post-Conditioning secreted in response to atrial stretch. BNP is also in atrial granules but is found in the highest level in ventricles of -atrial natriuretic NO triggers various physiologi ؍ ANP peptide stressed hearts (28). C-type NP is found at lower concentration cal responses by binding and ac- in vascular endothelium and is present in higher concentration B-type natriuretic tivating sGC to produce cGMP ؍ BNP peptide in chondrocytes where it stimulates long bone growth (29). In from guanosine triphosphate ,the cardiovascular system, NPs exhibit growth suppressive ؍ cAMP cyclic adenosine (18). NO-cGMP-PKG signal- monophosphate antiproliferative, and antihypertrophic actions on vascular ing pathway is involved in the .(cyclic guanosine smooth muscle cells, cardiomyocytes, and fibroblasts (30 ؍ cGMP cardioprotective action in I/R in- monophosphate ANP/BNP exert myocardial protective effects against I/R jury as a survival signal (19,20). doxorubicin injury through a cGMP-PKG–dependent modulation ؍ DOX In cardiomyocytes, cGMP re- of mitoK channels (31). ANP also protects against ؍ DMD Duchenne muscular duced the effects of myocyte stun- ATP dystrophy reoxygenation-induced hypercontracture in cardiomyo- ning after simulated I/R (21). The -guanylyl cyclase cytes by stimulating cGMP synthesis (32). Administra ؍ GC NO donor S-nitroso-N-acetyl- tion of ANP at reperfusion protected against I/R injury ؍ I/R ischemia-reperfusion L,L-penicillamine mimicked the -dystrophin-deficient (33,34) and exerted antiapoptotic effects in rat cardiomy ؍ mdx pre-conditioning–like effect by ocytes through cGMP-PKG and by inducing phospha- myocardial infarction ؍ MI inducing cGMP (22). Moreover, tidylinositol 3-kinase-protein kinase B (PI3K/AKT) sig- ؍ mitoKATP mitochondrial the activation of the NO/cGMP/ naling (35). cGMP analogue, 8-Br-cGMP, or elevation KATP PKG pathway inhibited the ele- ϩ of intracellular cGMP concentration via the sGC activator nitric oxide 2 ؍ NO vation of intracellular Ca con- NO or BNP exerted cardioprotective effects through PKG .(nitric oxide centrations by phosphorylating activation (36 ؍ NOS synthase target proteins responsible for in- ϩ Cinaciguat (BAY 58-2667) activates sGC independent of 2 ؍ NP natriuretic peptide tracellular Ca homeostasis during NO (37). This drug preferentially activates sGC when the phosphodiesterase I/R injury in Chinese hamster ؍ PDE .(particulate guanylyl ovary cells (23 ؍ pGC cyclase Ischemic pre-conditioning rap- cyclic guanosine idly increased cGMP levels via ؍ PKG monophosphate–dependent sGC during ischemia, leading to protein kinases delayed protective effect (24 h -soluble guanylyl later) against myocardial stun ؍ sGC cyclase ning and infarction in conscious rabbits (24). Bradykinin, one of the triggers of pre-conditioning, caused receptor-mediated production of NO resulting in cGMP production, activation of PKG, and opening of mitochondrial KATP (mitoKATP) chan- nel in rabbit heart and cardiomyocytes (25). Opening of mitoKATP channels causes partial compensation of the mem- brane potential, which enables additional protons to be ϩ pumped out to form a H electrochemical gradient for both ϩ adenosine triphosphate synthesis and Ca2 transport (26). The cGMP/PKG pathway also confers ischemic post-conditioning protection in part by delaying normalization of pH during ϩ reperfusion, probably via PKG-dependent inhibition of Na / ϩ H -exchanger in rat heart (27). cGMP Modulatory Drugs for Cardioprotection cGMP modulatory drugs induce cardioprotective effect Figure 1 Myocardial Protection by Up-Regulation of cGMP through PKG as outlined in Figure 1. NPs exert biological Cardioprotective modalities including pre-conditioning, post-conditioning, atrial effects by binding to membrane-associated pGC. Atrial natriuretic peptide (ANP)/B-type natriuretic peptide (BNP), nitric oxide (NO) natriuretic peptide (ANP), B-type natriuretic peptide donors, and Cinaciguat generate cyclic guanosine monophosphate (cGMP) (BNP), and C-type NP are 3 structurally related, but through activation of soluble guanylyl cyclase (sGC)/particulate guanylyl cyclase (pGC). cGMP exerts cardioprotective effects against ischemia/reperfusion injury genetically distinct, signaling molecules that regulate the through activation of cyclic
Load more

Recommended publications
  • Circulating Supar in Two Cohorts of Primary FSGS
    CLINICAL RESEARCH www.jasn.org Circulating suPAR in Two Cohorts of Primary FSGS † ‡ Changli Wei,* Howard Trachtman, Jing Li,* Chuanhui Dong, Aaron L. Friedman,§ | | | Jennifer J. Gassman, June L. McMahan, Milena Radeva, Karsten M. Heil,¶ †† ‡‡ Agnes Trautmann,¶ Ali Anarat,** Sevinc Emre, Gian M. Ghiggeri, Fatih Ozaltin,§§ || ††† Dieter Haffner, Debbie S. Gipson,¶¶ Frederick Kaskel,*** Dagmar-Christiane Fischer, ‡‡‡ Franz Schaefer,¶ and Jochen Reiser, for the PodoNet and FSGS CT Study Consortia Departments of *Medicine and ‡Neurology, University of Miami Miller School of Medicine, Miami, Florida; †Department of Pediatrics, NYU Langone Medical Center, New York, New York; §Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota; |Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; ¶Center for Pediatric and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany; **Department of Pediatric Nephrology, Cukurova University School of Medicine, Adana, Turkey; ††Department of Pediatrics, Istanbul Medical Faculty, University of Istanbul, Istanbul, Turkey; ‡‡Division of Nephrology, Dialysis, and Transplantation, Laboratory on Pathophysiology of Uremia, G. Gaslini Children’s Hospital, Genoa, Italy; §§Pediatric Nephrology Unit, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey; ||Department of Pediatric Kidney, Liver, and Metabolic Diseases, Hannover Medical School, Hannover, Germany; ¶¶Department of Pediatrics, University of Michigan, Ann Arbor, Michigan; ***Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York; †††Department of Pediatrics, Rostock University Hospital, Rostock, Germany; and ‡‡‡Department of Medicine, Rush University Medical Center, Chicago, Illinois ABSTRACT Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to pri- mary FSGS, and one recent study demonstrated elevated levels of serum suPAR in patients with the disease.
    [Show full text]
  • Identi®Cation and Role of Adenylyl Cyclase in Auxin Signalling in Higher
    letters to nature + + + P.P. thank the Academy of Finland and the Deutsche Forschungsgemeinschaft, respectively, for ®nancial CO , 53), 77 (C6H5 , 60), 73 (TMSi , 84); 6-methyl-4-hydroxy-2-pyrone: RRt 0.35, 198 (M+, 18), 183 ([M-Me]+, 16), 170 ([M-CO]+, 54), 155 ([M-CO-Me]+, support. + + Correspondence and requests for materials should be addressed to J.S. (e-mail: [email protected] 15), 139 ([M-Me-CO2] , 10), 127 ([M-Me-2CO] , 13), 99 (12), 84 (13), 73 + + freiburg.de). (TMSi , 100), 43 (CH3CO , 55). The numbers show m/z values, and the key fragments and their relative intensities are indicated in parentheses. Received 4 August; accepted 14 October 1998. erratum 1. Helariutta, Y. et al. Chalcone synthase-like genes active during corolla development are differentially expressed and encode enzymes with different catalytic properties in Gerbera hybrida (Asteraceae). Plant Mol. Biol. 28, 47±60 (1995). 2. Helariutta, Y. et al. Duplication and functional divergence in the chalcone synthase gene family of 8 Asteraceae: evolution with substrate change and catalytic simpli®cation. Proc. Natl Acad. Sci. USA 93, Crystal structure of the complex 9033±9038 (1996). 3. Thaisrivongs, S. et al. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2- of the cyclin D-dependent pyrones as effective, nonpeptidic inhibitors. J. Med. Chem. 39, 4630±4642 (1996). 4. Hagen, S. E. et al. Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the kinase Cdk6 bound to the profound effect of polarity on antiviral activity. J. Med. Chem.
    [Show full text]
  • 2'-Deoxyguanosine Toxicity for B and Mature T Lymphoid Cell Lines Is Mediated by Guanine Ribonucleotide Accumulation
    2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. Y Sidi, B S Mitchell J Clin Invest. 1984;74(5):1640-1648. https://doi.org/10.1172/JCI111580. Research Article Inherited deficiency of the enzyme purine nucleoside phosphorylase (PNP) results in selective and severe T lymphocyte depletion which is mediated by its substrate, 2'-deoxyguanosine. This observation provides a rationale for the use of PNP inhibitors as selective T cell immunosuppressive agents. We have studied the relative effects of the PNP inhibitor 8- aminoguanosine on the metabolism and growth of lymphoid cell lines of T and B cell origin. We have found that 2'- deoxyguanosine toxicity for T lymphoblasts is markedly potentiated by 8-aminoguanosine and is mediated by the accumulation of deoxyguanosine triphosphate. In contrast, the growth of T4+ mature T cell lines and B lymphoblast cell lines is inhibited by somewhat higher concentrations of 2'-deoxyguanosine (ID50 20 and 18 microM, respectively) in the presence of 8-aminoguanosine without an increase in deoxyguanosine triphosphate levels. Cytotoxicity correlates instead with a three- to fivefold increase in guanosine triphosphate (GTP) levels after 24 h. Accumulation of GTP and growth inhibition also result from exposure to guanosine, but not to guanine at equimolar concentrations. B lymphoblasts which are deficient in the purine salvage enzyme hypoxanthine guanine phosphoribosyltransferase are completely resistant to 2'-deoxyguanosine or guanosine concentrations up to 800 microM and do not demonstrate an increase in GTP levels. Growth inhibition and GTP accumulation are prevented by hypoxanthine or adenine, but not by 2'-deoxycytidine.
    [Show full text]
  • Soluble Guanylate Cyclase and Cgmp-Dependent Protein Kinase I Expression in the Human Corpus Cavernosum
    International Journal of Impotence Research (2000) 12, 157±164 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Soluble guanylate cyclase and cGMP-dependent protein kinase I expression in the human corpus cavernosum T Klotz1*, W Bloch2, J Zimmermann1, P Ruth3, U Engelmann1 and K Addicks2 1Department of Urology, University of Cologne; 2Institute I of Anatomy, University of Cologne; and 3Institute of Pharmacology, TU University of Munich, Germany Nitric oxide (NO) as a mediator in smooth muscle cells causes rapid and robust increases in cGMP levels. The cGMP-dependent protein kinase I has emerged as an important signal transduction mediator for smooth muscle relaxation. The purpose of this study was to examine the existence and distribution of two key enzymes of the NO=cGMP pathway, the cGMP-dependent kinase I (cGK I) and the soluble guanylate cyclase (sGC) in human cavernosal tissue. The expression of the enzymes were examined in corpus cavernosum specimens of 23 patients. Eleven potent patients suffered from penile deviations and were treated via Nesbit's surgical method. Nine long-term impotent patients underwent implantation of ¯exible hydraulic prothesis. Three potent patients underwent trans-sexual operations. Expression of the sGC and cGK I were examined immunohistochemically using speci®c antibodies. In all specimens of cavernosal tissue a distinct immunoreactivity was observed in different parts and structures. We found a high expression of sGC and cGK I in smooth muscle cells of vessels and in the ®bromuscular stroma. The endothelium of the cavernosal sinus, of the cavernosal arteries, and the cavernosal nerve ®bers showed an immunoreactivity against sGC.
    [Show full text]
  • A New Crystal Form of Bovine Pancreatic Rnase a in Complex with 2
    protein structure communications Acta Crystallographica Section F Structural Biology A new crystal form of bovine pancreatic RNase A in 000 and Crystallization complex with 2 -deoxyguanosine- Communications 5000-monophosphate ISSN 1744-3091 Steven B. Larson,a John S. Day,a The structure of bovine pancreatic RNase A has been determined in complex Robert Cudneyb and Alexander with 20-deoxyguanosine-50-monophosphate (dGMP) at 1.33 A˚ resolution at McPhersona* room temperature in a previously unreported unit cell belonging to space group P31. There are two molecules of nucleotide per enzyme molecule, one of which aDepartment of Molecular Biology and lies in the active-site cleft in the productive binding mode, whilst the guanine Biochemistry, The University of California, base of the other dGMP occupies the pyrimidine-specific binding site in a Irvine, CA 92697-3900, USA, and bHampton nonproductive mode such that it forms hydrogen bonds to the phosphate group Research, Aliso Viejo, CA 92656-3317, USA of the first dGMP. This is the first RNase A structure containing a guanine base in the B2 binding site. Each dGMP molecule is involved in intermolecular interactions with adjacent RNase A molecules in the lattice and the two Correspondence e-mail: [email protected] nucleotides appear to direct the formation of the crystal lattice. Because GMP may be produced during degradation of RNA, this association could represent Received 19 June 2007 an inhibitor complex and thereby affect the observed enzyme kinetics. Accepted 9 August 2007 PDB Reference: RNase A–dGMP complex, 2qca, r2qcasf. 1. Introduction Bovine pancreatic ribonuclease (EC 3.1.27.5), commonly known as RNase A, has been extensively studied by physical-chemical approaches and by X-ray crystallography for nearly 75 years.
    [Show full text]
  • Soluble Guanylate Cyclase B1-Subunit Expression Is Increased in Mononuclear Cells from Patients with Erectile Dysfunction
    International Journal of Impotence Research (2006) 18, 432–437 & 2006 Nature Publishing Group All rights reserved 0955-9930/06 $30.00 www.nature.com/ijir ORIGINAL ARTICLE Soluble guanylate cyclase b1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction PJ Mateos-Ca´ceres1, J Garcia-Cardoso2, L Lapuente1, JJ Zamorano-Leo´n1, D Sacrista´n1, TP de Prada1, J Calahorra2, C Macaya1, R Vela-Navarrete2 and AJ Lo´pez-Farre´1 1Cardiovascular Research Unit, Cardiovascular Institute, Hospital Clı´nico San Carlos, Madrid, Spain and 2Urology Department, Fundacio´n Jime´nez Diaz, Madrid, Spain The aim was to determine in circulating mononuclear cells from patients with erectile dysfunction (ED), the level of expression of endothelial nitric oxide synthase (eNOS), soluble guanylate cyclase (sGC) b1-subunit and phosphodiesterase type-V (PDE-V). Peripheral mononuclear cells from nine patients with ED of vascular origin and nine patients with ED of neurological origin were obtained. Fourteen age-matched volunteers with normal erectile function were used as control. Reduction in eNOS protein was observed in the mononuclear cells from patients with ED of vascular origin but not in those from neurological origin. Although sGC b1-subunit expression was increased in mononuclear cells from patients with ED, the sGC activity was reduced. However, only the patients with ED of vascular origin showed an increased expression of PDE-V. This work shows for the first time that, independently of the aetiology of ED, the expression of sGC b1-subunit was increased in circulating mononuclear cells; however, the expression of both eNOS and PDE-V was only modified in the circulating mononuclear cells from patients with ED of vascular origin.
    [Show full text]
  • Regulation of Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase (PDE1): Review
    95-105 5/6/06 13:44 Page 95 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 18: 95-105, 2006 95 Regulation of calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1): Review RAJENDRA K. SHARMA, SHANKAR B. DAS, ASHAKUMARY LAKSHMIKUTTYAMMA, PONNIAH SELVAKUMAR and ANURAAG SHRIVASTAV Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Cancer Research Division, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon SK S7N 4H4, Canada Received January 16, 2006; Accepted March 13, 2006 Abstract. The response of living cells to change in cell 6. Differential inhibition of PDE1 isozymes and its environment depends on the action of second messenger therapeutic applications molecules. The two second messenger molecules cAMP and 7. Role of proteolysis in regulating PDE1A2 Ca2+ regulate a large number of eukaryotic cellular events. 8. Role of PDE1A1 in ischemic-reperfused heart Calmodulin-stimulated cyclic nucleotide phosphodiesterase 9. Conclusion (PDE1) is one of the key enzymes involved in the complex interaction between cAMP and Ca2+ second messenger systems. Some PDE1 isozymes have similar kinetic and 1. Introduction immunological properties but are differentially regulated by Ca2+ and calmodulin. Accumulating evidence suggests that the A variety of cellular activities are regulated through mech- activity of PDE1 is selectively regulated by cross-talk between anisms controlling the level of cyclic nucleotides. These Ca2+ and cAMP signalling pathways. These isozymes are mechanisms include synthesis, degradation, efflux and seque- also further distinguished by various pharmacological agents. stration of cyclic adenosine 3':5'-monophosphate (cAMP) and We have demonstrated a potentially novel regulation of PDE1 cyclic guanosine 3':5'- monophosphate (cGMP) within the by calpain.
    [Show full text]
  • Sgc Stimulators and Activators
    International Cardiovascular Forum Journal 18 (2019) 2 | Reviews DOI: 10.17987/icfj.v18i0.609 sGC Stimulators and Activators Heli Tolppanen1, Piotr Ponikowski2 1. Helsinki University Central Hospital, Helsinki, Finland 2. Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland Corresponding author: Prof. Piotr Ponikowski, Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland. Email: [email protected] Abstract Nitric oxide (NO)-soluble guanylate cyclase(sGC)-cGMP signalling is impaired in HF syndromes, which could predispose to vascular oxidative stress. Nitrates directly stimulate cGMP, but are limited by tolerance. Therapeutic targets that aim at increasing cGMP concentrations have therefore been explored. Recently, two classes of drugs have been discovered, the sGC activators and the sGC stimulators, which target two different redox states of sGC: the NO-sensitive reduced (ferrous) sGC and NO-insensitive oxidized (ferric) sGC, respectively. Cinaciguat is an activator and riociguat and vericiguat are sGC stimulators. Vericiguat is the most advanced agent in its clinical trial programme with two completed phase IIb studies, SOCRATES -REDUCED in HFrEF and SOCRATES-PRESERVED in HFpEF, with mixed results on NT-proBNP. The ongoing VICTORIA trial in HFrEF will study 4,872 participants with a mortality/morbidity end-point and VITALITY HFpEF trial will study 735 participants, with a quality of life end- point. Keywords: heart failure; sGC activators; sGC stimulators; vericiguat Citation: Tolppanen H, Ponikowski P.
    [Show full text]
  • Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by The
    Molecular Pharmacology Fast Forward. Published on November 14, 2017 as DOI: 10.1124/mol.117.109918 This article has not been copyedited and formatted. The final version may differ from this version. MOL #109918 Irreversible activation and stabilization of soluble guanylate cyclase by the protoporphyrin IX mimetic cinaciguat Alexander Kollau, Marissa Opelt, Gerald Wölkart, Antonius C.F. Gorren, Michael Russwurm, Doris Koesling, Bernd Mayer and Astrid Schrammel Downloaded from Department of Pharmacology and Toxicology, University of Graz, Austria molpharm.aspetjournals.org (A.K., M.O., G.W., A.C.F.G., B.M., A.S.) Department of Pharmacology and Toxicology, Ruhr University Bochum, Bochum, Germany (M.R., D.K.) at ASPET Journals on September 29, 2021 1 Molecular Pharmacology Fast Forward. Published on November 14, 2017 as DOI: 10.1124/mol.117.109918 This article has not been copyedited and formatted. The final version may differ from this version. MOL #109918 Running Title: Irreversible activation of sGC by cinaciguat Address correspondence to: Dr. Astrid Schrammel Department of Pharmacology and Toxicology Karl-Franzens-Universität Graz Humboldtstrasse 46, A-8010 Graz, Austria Downloaded from Tel.: +43-316-380-5559 Fax: +43-316-380-9890 e-mail: [email protected] molpharm.aspetjournals.org Number of text pages: 24 Number of tables: – at ASPET Journals on September 29, 2021 Number of figures: 3 Number of references: 27 Number of words in Abstract: 236 Introduction: 436 Discussion: 904 1Abbreviations: DEA/NO, 2,2-diethyl-1-nitroso-oxyhydrazine; DTT, dithiothreitol; IBMX, 3-isobutyl-1-methylxanthin; NO, nitric oxide; ODQ, 1H-[1,2,4]oxadiazolo-[4,3- a]quinoxalin-1-one; PDE, phosphodiesterase; sGC, soluble guanylate cyclase; 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
    International Journal of Molecular Sciences Review Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation Elizabeth C. Wittenborn and Michael A. Marletta * California Institute for Quantitative Biosciences, Departments of Chemistry and of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA; [email protected] * Correspondence: [email protected] Abstract: The enzyme soluble guanylate cyclase (sGC) is the prototypical nitric oxide (NO) receptor in humans and other higher eukaryotes and is responsible for transducing the initial NO signal to the secondary messenger cyclic guanosine monophosphate (cGMP). Generation of cGMP in turn leads to diverse physiological effects in the cardiopulmonary, vascular, and neurological systems. Given these important downstream effects, sGC has been biochemically characterized in great detail in the four decades since its discovery. Structures of full-length sGC, however, have proven elusive until very recently. In 2019, advances in single particle cryo–electron microscopy (cryo-EM) enabled visualization of full-length sGC for the first time. This review will summarize insights revealed by the structures of sGC in the unactivated and activated states and discuss their implications in the mechanism of sGC activation. Keywords: nitric oxide; soluble guanylate cyclase; cryo–electron microscopy; enzyme structure Citation: Wittenborn, E.C.; Marletta, 1. Introduction M.A. Structural Perspectives on the Soluble guanylate cyclase (sGC) is a nitric oxide (NO)-responsive enzyme that serves Mechanism of Soluble Guanylate as a source of the secondary messenger cyclic guanosine monophosphate (cGMP) in Cyclase Activation. Int. J. Mol. Sci. humans and other higher eukaryotes [1]. Upon NO binding to sGC, the rate of cGMP 2021, 22, 5439.
    [Show full text]
  • A Nitric Oxide/Cysteine Interaction Mediates the Activation of Soluble Guanylate Cyclase
    A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase Nathaniel B. Fernhoffa,1, Emily R. Derbyshirea,1,2, and Michael A. Marlettaa,b,c,3 Departments of aMolecular and Cell Biology and bChemistry, University of California, Berkeley, CA 94720; and cCalifornia Institute for Quantitative Biosciences and Division of Physical Biosciences, Lawrence Berkeley National Laboratory, Berkeley, CA 94720 Contributed by Michael A. Marletta, October 1, 2009 (sent for review August 22, 2009) Nitric oxide (NO) regulates a number of essential physiological pro- high activity of the xsNO state rapidly reverts to the low activity of cesses by activating soluble guanylate cyclase (sGC) to produce the the 1-NO state. Thus, all three sGC states (basal, 1-NO, and xsNO) second messenger cGMP. The mechanism of NO sensing was previ- can be prepared and studied in vitro (7, 8). Importantly, these ously thought to result exclusively from NO binding to the sGC heme; results define two different states of purified sGC with heme bound however, recent studies indicate that heme-bound NO only partially NO (7, 8), one with a high activity and one with a low activity. activates sGC and additional NO is involved in the mechanism of Further evidence for a non-heme NO binding site was obtained maximal NO activation. Furthermore, thiol oxidation of sGC cysteines by blocking the heme site with the tight-binding ligand butyl results in the loss of enzyme activity. Herein the role of cysteines in isocyanide, and then showing that NO still activated the enzyme NO-stimulated sGC activity investigated. We find that the thiol mod- (14).
    [Show full text]
  • GUCY2F Protein Recombinant Human Protein Expressed in Sf9 Cells
    Catalog # Aliquot Size G12-31G-20 20 µg G12-31G-50 50 µg GUCY2F Protein Recombinant human protein expressed in sf9 cells Catalog # G12-31G Lot # U1858-3 Product Description Purity Recombinant human GUCY2F (367-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The gene accession number is BC156674. The purity of GUCY2F protein was determined to be >70% by Gene Aliases densitometry, GUCY2F approx. MW 110kDa. CYGF, GC-F, GUC2DL, GUC2F, RETGC-2, ROS-GC2 Formulation Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. Storage and Stability Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Scientific Background Guanylate cyclase 2F (GUCY2F) belongs to the adenylyl cyclase class-4/guanylyl cyclase family which also includes GUCY2D. Both GUCY2F and GUCY2D are responsible for the replenishment of cGMP in photoreceptors after exposure to light and are required for the normal kinetics of photoreceptor sensitivity and recovery, although disease mutations are restricted to GUCY2F Protein Full-length recombinant human protein expressed in sf9 cells GUCY2D. Catalog # G12-31G References Lot # U1858-3 1. Goraczniak R, et al: Structural and functional characteri- Purity >70% Concentration 0.05 µg/µl zation of a second subfamily member of the calcium- Stability 1yr at –70oC from date of shipment modulated bovine rod outer segment membrane Storage & Shipping Store product at –70oC.
    [Show full text]